131 related articles for article (PubMed ID: 16395672)
1. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations.
Mathe E; Olivier M; Kato S; Ishioka C; Vaisman I; Hainaut P
Hum Mutat; 2006 Feb; 27(2):163-72. PubMed ID: 16395672
[TBL] [Abstract][Full Text] [Related]
2. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
3. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.
Mathe E; Olivier M; Kato S; Ishioka C; Hainaut P; Tavtigian SV
Nucleic Acids Res; 2006; 34(5):1317-25. PubMed ID: 16522644
[TBL] [Abstract][Full Text] [Related]
4. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
5. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
6. p53 mutants without a functional tetramerisation domain are not oncogenic.
Chène P; Bechter E
J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
[TBL] [Abstract][Full Text] [Related]
7. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
8. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
9. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
10. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations.
Soussi T; Kato S; Levy PP; Ishioka C
Hum Mutat; 2005 Jan; 25(1):6-17. PubMed ID: 15580553
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
[TBL] [Abstract][Full Text] [Related]
13. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions.
Inga A; Nahari D; Velasco-Miguel S; Friedberg EC; Resnick MA
Oncogene; 2002 Aug; 21(37):5704-15. PubMed ID: 12173040
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
15. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
16. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.
Kawaguchi T; Kato S; Otsuka K; Watanabe G; Kumabe T; Tominaga T; Yoshimoto T; Ishioka C
Oncogene; 2005 Oct; 24(46):6976-81. PubMed ID: 16007150
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
18. Accurate prediction of enzyme mutant activity based on a multibody statistical potential.
Masso M; Vaisman II
Bioinformatics; 2007 Dec; 23(23):3155-61. PubMed ID: 17977887
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
20. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]